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ffect of Sleep Loss on C-Reactive Protein,
n Inflammatory Marker of Cardiovascular Risk
ans K. Meier-Ewert, MD,* Paul M. Ridker, MD, MPH,† Nader Rifai, PHD,‡
eredith M. Regan, SCD,§ Nick J. Price, David F. Dinges, PHD,¶ Janet M. Mullington, PHD#
urlington and Boston, Massachusetts; and Philadelphia, Pennsylvania
OBJECTIVES We sought to investigate the effects of sleep loss on high-sensitivity C-reactive protein (CRP)
levels.
BACKGROUND Concentrations of high-sensitivity CRP are predictive of future cardiovascular morbidity. In
epidemiologic studies, short sleep duration and sleep complaints have also been associated
with increased cardiovascular morbidity. Two studies were undertaken to examine the effect
of acute total and short-term partial sleep deprivation on concentrations of high-sensitivity
CRP in healthy human subjects.
METHODS In Experiment 1, 10 healthy adult subjects stayed awake for 88 continuous hours. Samples of
high-sensitivity CRP were collected every 90 min for 5 consecutive days, encompassing the
vigil. In Experiment 2, 10 subjects were randomly assigned to either 8.2 h (control) or 4.2 h
(partial sleep deprivation) of nighttime sleep for 10 consecutive days. Hourly samples of
high-sensitivity CRP were taken during a baseline night and on day 10 of the study protocol.
RESULTS The CRP concentrations increased during both total and partial sleep deprivation conditions,
but remained stable in the control condition. Systolic blood pressure increased across
deprivation in Experiment 1, and heart rate increased in Experiment 2.
CONCLUSIONS Both acute total and short-term partial sleep deprivation resulted in elevated high-sensitivity
CRP concentrations, a stable marker of inflammation that has been shown to be predictive
of cardiovascular morbidity. We propose that sleep loss may be one of the ways that
inflammatory processes are activated and contribute to the association of sleep complaints,
short sleep duration, and cardiovascular morbidity observed in epidemiologic surveys. (J Am
Coll Cardiol 2004;43:678–83) © 2004 by the American College of Cardiology Foundationh
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ileep complaints and short sleep duration are associated
ith increased cardiovascular morbidity in a series of epi-
emiologic surveys (1–6) and in a recent case-control study
f overtime work and insufficient sleep (7). Although the
echanism for this association is not known, it is of
articular interest that experimental sleep deprivation in
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eurology, Harvard Medical School, and Beth Israel Deaconess Medical Center,
oston, Massachusetts. Experiment 1 was funded by two awards to Dr. Dinges from
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isted as a co-inventor on patents that relate to the use of inflammatory biomarkers in
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Manuscript received June 1, 2003; revised manuscript received July 14, 2003,accepted July 22, 2003.ealthy adults has been found to lead to increased peripheral
irculation of leukocytes (8,9) and interleukin (IL)-6 (10).
his suggests that sleep loss itself may contribute to
nflammation and, if chronic, to cardiovascular risk.
C-reactive protein (CRP) is a pentameric hepatocyte
rotein with a half-life of 15 to 19 h (11) and is the major
arker of the “acute-phase response,” or the formation of
lasma proteins in response to an inflammatory stimulus, in
umans (12). Synthesis of CRP in the liver is largely
ontrolled by interleukin (IL)-6 and also by tumor necrosis
actor-alpha and IL-1 (13). The production of CRP is
hought to reflect the activity of these cytokines, particularly
L-6 (14). Although IL-6 levels display circadian variability,
RP levels have been shown to be quite stable across 24 h
15) and, in the absence of disease, are quite reproducible,
ven over weeks and months (16).
In recent years, since the advent of high-sensitivity
echnology permitting measurement of CRP levels as low as
.007 mg/dl from the previous detection limits of 3 to 5
g/dl (17), epidemiologic studies have pointed to CRP as a
redictor of both a long- and short-term risk of stroke and
yocardial infarction in men and women (18,19).
-reactive protein has been shown to promote secretion of
nflammatory mediators by vascular endothelium (20,21)
nd opsonizes low-density lipoprotein for uptake by mac-
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February 18, 2004:678–83 CRP in Sleep Deprivationophages in atherosclerotic plaque (22). These data suggest
hat CRP may be directly implicated in the development of
therosclerotic lesions.
We hypothesize that inflammatory processes are activated
y inadequate sleep. C-reactive protein was recently re-
orted to be elevated in patients with obstructive sleep
pnea, raising the possibility that deprivation of sleep, due
o its disruption via untreated apnea, contributes to inflam-
ation (23). The current investigation directly examined
his hypothesis in two experiments in healthy adults exposed
o three nights of total sleep loss and 10 consecutive nights
f partial sleep loss. It was hypothesized that if sleep loss
ontributed to the inflammatory response associated with
levated cardiovascular risk, it would not only upregulate
RP but do so in a dose-dependent manner related to the
agnitude of sleep lost.
ETHODS
xperiment 1: acute total sleep deprivation (TSD).
ubjects included 10 healthy male volunteers between the
ges of 22 and 37 years (average 27.2 years), who gave
igned, informed consent to participate in the research
rotocol, approved by the Institutional Review Board of the
niversity of Pennsylvania, before undergoing screening
ests. Inclusion in the study required that subjects be healthy
nd free of signs and symptoms of active infection. Inclusion
urther required complete blood cell counts and chemistry
ests within normal limits on all parameters in one or more
restudy assessments; toxicology reports free of medications
nd drugs; no medical history of cancer, hepatitis, or other
erious conditions; age-appropriate normal limits of physical
nd psychological health; and evidence of a stable sleep/
ake pattern defined by a habitual nocturnal sleep duration
f 6.5 to 9.0 h and habitual morning awakening between
:00 and 9:00 AM. Sleep/wake patterns were verified using
rist actigraphy for at least one week before the laboratory
tudy.
ROTOCOL. Subjects spent 10 days (24-h periods) in the
ational Institutes of Health (NIH) General Clinical Re-
earch Center (GCRC) of the Hospital of the University of
ennsylvania. After three baseline days with bed periods
etween 11:30 PM and 7:30 AM, subjects underwent 88 h of
SD, as a placebo-control group in a double-blind trial of
Abbreviations and Acronyms
ANOVA  analysis of variance
BP  blood pressure
GCRC  General Clinical Research Center
HR  heart rate
CRP  C-reactive protein
IL  interleukin
PSD  partial sleep deprivation
TSD  total sleep deprivationustained low-dose caffeine. During the period of blood collection and sleep deprivation, subjects were confined to a
emperature-controlled, time-isolated hospital room in50
ux of ambient light. They were prohibited from exercise,
aintained on a balanced diet (caffeine, tobacco, alcohol,
nd other psychoactive substances were prohibited), and
ehaviorally monitored to ensure they remained awake
hroughout the 88-h vigil. The GCRC nurses made daily
easurements of heart rate (HR) and blood pressure (BP).
ubjects were instrumented for continuous physiologic
onitoring of electroencephalographic, electrooculo-
raphic, and electrocardiographic signals, as well as rectal
ody temperature, and were required to perform a comput-
rized neurobehavioral test battery (performance, mood,
ymptoms) for approximately 30 min every 2 h throughout
ll waking periods. After the 88-h vigil, subjects remained in
he laboratory for three days for recovery sleep and testing.
For a five-day period from the second baseline night of
leep until the end of the first recovery day, blood samples
ere obtained at 90-min intervals via an indwelling venous
orearm catheter (Fig. 1, left panel). Eight samples per day
ere assayed for CRP levels, as described subsequently.
xperiment 2: short-term partial sleep deprivation (PSD).
en healthy volunteers (6 men and 4 women; age 26 to 38
ears [average 30.1 years]) participated in the study. The
nstitutional Review Board of the University of Pennsylva-
ia approved the research protocol, and subjects gave
ritten, informed consent before going through screening
rocedures, as in Experiment 1.
ROTOCOL. Subjects spent 14 days (13 nights) in 50 lux
mbient light in a time-isolated, temperature-controlled
leep and Chronobiology Laboratory, which is a satellite of
he NIH GCRC of the Hospital of the University of
ennsylvania. They had a scheduled 8.2-h time in bed for
he first two nights in the protocol and were randomly
ssigned in balanced order to one of two experimental
igure 1. Schematic of acute total sleep deprivation (TSD) protocol (left
anel) and short-term partial sleep deprivation (PSD) protocol (right
anel). Bars represent 24-h periods from 9:00 PM to 9:00 PM for TSD and
:00 PM to 5:00 PM PSD. Solid bars  sleep periods for the acute TSD
ubjects (left panel) and for the PSD subjects (right panel). Hatched
ars  sleep periods for the 8.2-h control group in the PSD experiment
right panel). bl  baseline; r  recovery; #  frequent blood sampling days.onditions. Daily assessment of HR and BP was made by
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CRP in Sleep Deprivation February 18, 2004:678–83CRC nurses. Five subjects were allocated to each the
hort-term PSD and control condition. Group assignment
as comparable for age, gender, and body mass index (21 to
1.1 kg/m2 [median 24.6 kg/m2]). One subject in the
leep-restriction condition was excluded because of difficulty
btaining blood. Subjects in the sleep-restriction condition
ad 4.2 h of available time in bed (between midnight and
:00 AM) for sleep each night for the next 10 consecutive
ights. Subjects in the control condition continued with
.2 h (between 10:00 PM and 6:00 AM) per night for the next
0 nights of study. After the 10 days, subjects in both
onditions were permitted 14 h of recovery sleep. Through-
ut all wake periods, subjects were behaviorally monitored
o ensure that they remained awake.
Outside of blood collection days, throughout scheduled
ake periods, subjects were tested, as in experiment 1, on a
omputerized neurobehavioral battery of tests. Ambulatory
lectroencephalograms and electrooculograms and rectal
ody temperature were also monitored. Nutritionally bal-
nced meals were provided throughout the protocol, at
ppropriate times for breakfast, lunch, and dinner (caffeine,
obacco, alcohol, and other psychoactive substances were
rohibited). As in Experiment 1, subjects were not permit-
ed to have visitors during the protocol.
Blood samples were collected on the first baseline day and
n the day 10 (end) of the experimental period, via an
ndwelling forearm nonthrombogenic catheter and line
sing a pump system (ConFlo, Stockholm, Sweden). Sub-
ects remained in bed (except for bathroom breaks) through-
ut blood collection. Integrated samples were collected
very 15 min (Fig. 1, right panel) and assayed for CRP at
ourly intervals.
PECIMEN PROCESSING. Blood samples from Experiment 1
ere stabilized with ethylenediamine tetraacetic acid
EDTA) and aprotinin (300 kallikrein-inhibiting U/ml
lood). Blood samples from Experiment 2 were stabilized
ith EDTA. All blood samples were set on ice for 5 min
efore centrifugation at 2,600g for 7 min at 4°C. After
entrifugation, plasma was pipetted into polypropylene
ubes and frozen at 70°C until thawed for analysis.
SSAYS. Determination of high-sensitivity CRP concentra-
ions was performed using an ultrasensitive latex-enhanced
mmunoassay (Dade Behring, Newark, Delaware) (16).
ay-to-day imprecision for the CRP assay at concentra-
ions of 0.06 and 1.26 mg/dl were 8.8% and 4.3%, respec-
ively. Concentrations of CRP below the detection level of
he CRP assay (0.02 mg/dl) were assigned a value of 0.01
g/dl. Missing values were replaced by interpolated values.
issing values accounted for 45 of 400 data points in
xperiment 1 and 21 of 450 data points in experiment 2.
tatistical analysis. As the distribution of CRP was posi-
ively skewed, data were log-transformed before analysis.
or ease of interpretation, where reported, the mean value
SEM was transformed from the log-scale back to the
sual scale (mg/dl) (i.e., geometric mean). cIn Experiment 1 (acute TSD), daily averages of CRP
ere calculated (from samples taken at 3-h intervals for a
otal of 8 time points per day) for each subject and then
og-transformed. The log CRP concentrations over time,
R, and BP were analyzed using mixed-models analysis of
ariance (ANOVA); if the effect of time was statistically
ignificant (p  0.05), then model contrasts were used to
ompare subsequent days with baseline. The p values were
ot adjusted for multiple comparisons.
In Experiment 2 (short-term PSD), daily averages of
RP were calculated for baseline and day 10 of PSD and
hen log-transformed. The log CRP concentrations, HR,
nd BP were analyzed using mixed-models ANOVA with
actors for study day, sleep condition, and the interaction; if
he interaction was statistically significant (p  0.10), then
odel contrasts were used to compare day 10 with baseline
or each sleep condition. The p values were not adjusted for
ultiple comparisons.
Baseline values of log CRP concentration, HR, and BP
ere pooled from Experiments 1 and 2, and Pearson
orrelation coefficients of log CRP with HR and BP were
alculated. The statistical analysis was performed using SAS
ersion 8.0 (SAS Institute Inc., Cary, North Carolina).
ESULTS
xperiment 1: acute TSD. The CRP concentrations in-
reased steadily and significantly over the five-day period, as
epicted in Figure 2. The daily averages were 0.039 0.013
g/dl at baseline; 0.048  0.016 mg/dl for the first, 0.058
0.020 mg/dl for the second, and 0.065 0.023 mg/dl for
he third sleep deprivation days; and 0.066  0.024 mg/dl
t recovery. The fixed effect for time was significant: F(4,9)
4.43, p  0.03. Pairwise comparisons showed that CRP
igure 2. Data were log-transformed before analysis. For ease of interpre-
ation, the mean values  SEM were transformed from the log scale back
o the usual scale (mg/dl) in 10 subjects undergoing 88 h of acute total sleep
eprivation. Overall p  0.03 by mixed-models analysis of variance on
og-transformed data; each subsequent day is significantly elevated (each p
0.05) from baseline. The upper portion of the graph represents the
oundary separating the low- and mild-risk quintiles of C-reactive protein
CRP) derived from analysis of5,000 apparently healthy Americans (16).
L  baseline; Dep  deprivation.oncentrations were significantly increased over baseline
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February 18, 2004:678–83 CRP in Sleep Deprivationevels on each of the sleep deprivation days and remained
levated on the recovery day (each p  0.05) (Fig. 2).
Table 1 provides the daily HR and systolic and diastolic
P measurements for TSD subjects on each day of blood
ollection. There was a significant increase in systolic BP
hrough the five-day protocol. Diastolic BP and HR showed
rends in the same direction.
xperiment 2: short-term PSD. The CRP levels in-
reased significantly from 0.051  0.020 mg/dl at baseline
8.2 h of time in bed/night) to 0.265 0.131 mg/dl (t[7]
.45, p  0.05) on the tenth day of short-term PSD (4.2 h
f time in bed/night) in experiment 2 (Fig. 3). Subjects in
he 8.2-h condition (8.2 h in bed per night throughout the
tudy) went from 0.136  0.047 mg/dl to 0.110  0.049
g/dl, which was not significant (t[7]  0.36, p  0.72).
he interaction between study day and sleep condition
pproached significance: F(1,7)  4.28, p  0.08.
Table 2 provides the daily HR and systolic and diastolic
P measurements for PSD subjects on the baseline day of
lood collection and on the tenth day of the experimental
eriod. The only significant interaction was for HR, which
as found to increase significantly in the PSD group. There
as no significant interaction for systolic or diastolic BP.
Data from Experiments 1 and 2 were subsequently
ooled for the baseline measures. Heart rate and systolic and
iastolic BP were correlated with the log-transformed CRP
ata. We found a correlation of 0.52 (p 0.05) with systolic
igure 3. Data were log-transformed before analysis. For ease of interpre-
ation, the mean values  SEM were transformed from the log scale back
o the usual scale (mg/dl) in subjects undergoing 10 consecutive days of
hort-term partial sleep deprivation (n  4, squares) and control subjects
n  5, diamonds). Significance of difference in change from baseline to
ay 10 between groups (p 0.08 for interaction) by mixed-models analysis
f variance on log-transformed data: the change from baseline to day 10 for
he short-term partial sleep deprivation group was significant (p  0.05),
hereas the change from baseline to day 10 in the control subjects was not
ignificant (p  0.72). The horizontal lines indicate risk boundaries (mild
o highest) of C-reactive protein (CRP) quintiles derived from analysis of
able 1. Heart Rate and Blood Pressure During Total Sleep Dep
Baseline
BL
(n  8)
Dep 1
(n  8)
Dep
(n 
eart rate (beats/min) 63.0  3.5 65.1  3.7 70.1
ystolic BP (mm Hg) 121.1  3.8 122.5  2.7 125.4
iastolic BP (mm Hg) 68.1  2.9 70.0  2.4 72.0
ata are presented as the mean value  SEM.
BL  baseline; BP  blood pressure; Dep  deprivation (day).t5,000 apparently healthy Americans (16).nd 0.49 (p  0.10) with diastolic BP. There was insuffi-
ient data to examine correlations in each experiment
eparately, after sleep deprivation.
ISCUSSION
he results of these two experiments demonstrate that both
cute TSD and short-term PSD raise basal concentrations
f CRP in healthy volunteers, without signs or symptoms of
nfection. Furthermore, the 60% increase relative to base-
ine, seen across 88 h of TSD, appeared to be linear and
ose-dependent. The CRP levels climbed during the 88-h
igil, through the low prediction zone (0.01 to 0.07 mg/dl),
nd approached levels associated with mild risk (0.07 to
.11 mg/dl) for myocardial infarction and stroke (19). In the
SD study, subjects moved from levels consistent with mild
isk to levels representing values seen in the highest risk
uintile of CRP concentrations (0.38 to 1.50 mg/dl) derived
rom population studies (19). In this condition, from day 1
o 10, there was an increase of more than fourfold. When
he one outlying observation is eliminated from this group
on day 10, CRP  1.24 mg/dl), there is still a three-fold
ncrease, from an average of 0.051 on day 1 to 0.158 mg/dl
n day 10 of PSD.
Although this study is the first to describe basal increases
n high-sensitivity CRP in relation to sleep loss, subclinical
ffects of sleep restriction on inflammatory and immuno-
ogic parameters have been reported earlier. Sleep depriva-
ion for between 36 and 64 h (8,9) has been shown to
ncrease the number of leukocytes in the peripheral circu-
ation. More recently, increased IL-6 plasma concentrations
ere found after sleep deprivation for 24 h (24) and 88 h
10). Neurobehavioral signs and symptoms of fatigue and
leepiness are induced in subjects undergoing acute TSD (8)
nd short-term PSD (25). Furthermore, a low-dose IL-6
njection leads to increased subjective estimates of fatigue
26). These results are consistent with studies of patients
ith excessive daytime sleepiness, in whom these symptoms
ave been associated with increased systemic IL-6 concen-
rations (27,28). They also support the hypothesis that one
ay in which CRP is elevated in patients with untreated
bstructive sleep apnea is through deprivation of restorative
leep (23).
In several epidemiologic studies, sleep complaints were
ndependently associated with an increased likelihood of
ardiovascular morbidity or death. Appels et al. (1) reported
ion
Dep 3
(n  8)
Recovery 1
(n  7) Significance
70.9  2.8 69.7  2.9 F(4,7)  3.3, p  0.10
128.9  3.0 130.0  4.2 F(4,7)  313.3, p  0.0001
72.9  2.8 71.4  3.6 F(4,7)  3.4, p  0.10rivat
2
7)
 3.3
 6.4
 4.0hat difficulty falling asleep or maintaining sleep, as assessed
b
i
c
f
i
i
C
c
d
c
e
v
s
i
(
d
i
a
d
s
i
A
r
(
i
t
i
y
d
l
d
t
a
d
r
t
r
r
b
t
t
t
c
s
i
f
f
a
m
s
T
m
e
c
e
s
m
s
p
c
d
e
d
I
s
r
s
P
f
i
p
a
t
w
t
t
i
f
k
s
C
f
682 Meier-Ewert et al. JACC Vol. 43, No. 4, 2004
CRP in Sleep Deprivation February 18, 2004:678–83y a questionnaire in middle-aged women, significantly
ncreased the risk for nonfatal myocardial infarction or
ardiovascular death, even after adjustment for multiple risk
actors of coronary heart disease. Similar results were found
n middle-aged men in the Framingham population (2) and
n older subjects in the Piedmont Health Survey (3) and the
ardiovascular Health Study (4). Furthermore, it has re-
ently been reported that individuals sleeping for short
urations are at increased risk of myocardial infarction (5,6).
One hypothesis for the link between increased cardiovas-
ular risk and elevated CRP is that vascular shear stress
xacerbated by increased BP leads to inflammation in the
ascular wall. A quantitative positive relationship has been
hown between increasing BP and levels of IL-6 and
ntercellular adhesion molecule-1 in apparently healthy men
29). The association between elevated CRP and sleep
eprivation in our subjects may also be related to BP
ncreases. We found that systolic BP was increased in our
cute TSD subjects, and there were trends toward increased
iastolic BP and HR. This confirms findings from another
tudy of normal, healthy controls in whom there was an
ncrease in BP after a single night of sleep deprivation (30).
ltered cardiovascular output has also been previously
eported in PSD after four nights of sleep for 4 h per night
31). In that study, systolic BP, but not HR, was found to
ncrease. The potential clinical importance is suggested by
he finding that a single night of 50% reduced sleep resulted
n increased systolic and diastolic BP and HR (32).
Sleep loss may be an important contributing factor in as
et unexplained associations between inflammation and
isease. Experimentally induced acute TSD (33) and cumu-
ative partial sleep loss (34) have been associated with
ecreased glucose sensitivity and insulin resistance, respec-
ively. Furthermore, a self-reported short sleep length is
ssociated with an increased risk of the development of
iabetes, and increased weight gain may mediate this
elationship (35). Small elevations in inflammatory media-
ors have also been associated with the syndrome of insulin
esistance and type II diabetes mellitus, independent of the
elationship of these conditions with adiposity (36), and
aseline CRP concentrations in nondiabetic subjects predict
he development of type II diabetes mellitus (37). Statin-
ype drugs, which are known to decrease CRP (38), decrease
Table 2. Heart Rate and Blood Pressure Durin
Baseline BL Dep 1
HR in sleep (beats/min) 75.0  4.1 79.5 
HR in PSD (beats/min) 75.2  2.6 97.0 
SBP in sleep (mm Hg) 127.8  6.2 137.3 
SBP in PSD (mm Hg) 113.6  6.7 135.2 
DBP in sleep (mm Hg) 73.5  7.4 86 
DBP in PSD (mm Hg) 68.6  3.0 85.4 
Data are presented as the mean value  SEM.
DBP  diastolic blood pressure; HR  heart rate; PSD
abbreviations as in Table 1.he incidence of cardiovascular events and have been asso- miated with a decrease in the development of diabetes (39),
uggesting that inflammation may be involved in mediating
nsulin resistance. In sleep-disordered breathing, sleep is
requently fragmented or otherwise reduced and evidence
or a strong relationship between obstructive sleep apnea
nd cardiovascular risk or cerebrovascular disease (40,41) is
ounting. Recently, evidence of a link between obstructive
leep apnea and elevated CRP has been demonstrated (23).
he current data raise the possibility that sleep loss alone
ay be an important contributing factor in the observed
levations in CRP.
Other changes associated with sleep loss may have also
ontributed to the increases in CRP encountered in our
xperiments. In vitro studies have suggested an influence of
teroids in the synthesis of CRP (13). Nonlinear mixed-
odels regression found significant increases in daily corti-
ol levels during the 88-h vigil of Experiment 1 (t  2.82,
 0.018). Furthermore, the circadian nadir in cortisol
oncentrations has been shown to increase during sleep
eprivation (42,43), and evening cortisol levels were also
levated in a PSD study (34).
Similarly, increased body mass has been shown to pre-
ispose to cytokinemia due to the synthesis and release of
L-6 from adipose tissue (44). However, diets were de-
igned to maintain body weight, and therefore weight
emained stable throughout the study. Body mass index was
imilar in both the experimental and control groups in the
SD condition and, in general, was well within the range
or an age-matched U.S. population. However, body mass
ndex was correlated with baseline CRP levels in subjects
ooled from both studies (Spearman’s r  0.60, n  19),
nd individual differences in the response to sleep depriva-
ion, as a function of adiposity, warrant further study.
The participants in the current studies were normal sleepers
ho underwent sleep deprivation for relatively brief periods of
ime; therefore, the results cannot be generalized to popula-
ions of habitually short-duration sleepers. The present exper-
ments also did not assess the CRP levels after full recovery
rom the sleep deficit induced by TSD and PSD, so it is not
nown how long the CRP elevations persisted, but current
tudies are underway to investigate this issue.
onclusions. Our findings support the hypothesis that
ailure to obtain adequate amounts of healthy sleep pro-
rtial Sleep Deprivation
Condition by Day
Interaction BL vs. Day 10
F(1,7)  5.89, p  0.05 NS
t(7)  4.59, p  0.01
NS
NS
tial sleep deprivation; SBP  systolic blood pressure; otherg Pa
0
7.3
4.8
3.5
9.4
2.9
4.8
 parotes low-level systemic inflammation. These studies raise
t
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February 18, 2004:678–83 CRP in Sleep Deprivationhe possibility that apparently healthy individuals may
otentiate a major marker of inflammation associated with
n increased risk of cardiovascular illness through the
ccumulation of a sleep deficit.
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